Table 3

Odds ratios of developing RA overall, ACPA-positive RA, or ACPA-negative RA among carriers of SE alleles compared with individuals without SE alleles in MyEIRA

All

Men

Women

Ca/Co

OR (95% CI)

Ca/Co

OR (95% CI)

Ca/Co

OR (95% CI)

All RA

No SE allele

629/1,183

1.0

83/181

1.0

546/1,002

1.0

Any SE alleles

425/233

3.0 (2.4 to 3.7)

68/30

4.5 (2.6 to 7.8)

357/203

2.8 (2.3 to 3.5)

ACPA-positive RA

No SE allele

334/1,183

1.0

45/181

1.0

289/1,002

1.0

Any SE alleles

345/233

4.7 (3.6 to 6.2)

59/30

8.0 (3.7 to 17.2)

286/203

4.3 (3.2 to 5.7)

HLA-DRB1*04:05

158/86

6.5 (4.9 to 8.7)

29/16

7.3 (3.3 to 14.6)

129/70

6.4 (4.6 to 8.8)

Non-HLA-DRB1*04:05 SE alleles

187/147

4.5 (3.5 to 5.8)

30/14

8.6 (4.2 to 17.6)

157/133

4.1 (3.1 to 5.3)

ACPA-negative RA

No SE allele

295/1,183

1.0

38/181

1.0

257/1,002

1.0

Any SE alleles

80/233

1.2 (0.8 to 1.7)

9/30

1.5 (0.6 to 3.9)

71/203

1.2 (0.8 to 1.7

HLA-DRB1*04:05

26/86

1.2 (0.8 to 1.9)

4/16

1.2 (0.4 to 3.8)

22/70

1.2 (0.7 to 2.0)

Non-HLA-DRB1*04:05 SE alleles

54/147

1.5 (1.1 to 2.1)

5/14

1.7 (0.6 to 5.0)

49/133

1.4 (1.0 to 2.0)

ACPA, anti-cyclic citrullinated proteins antibody; Ca/Co, the number of exposed cases/number of exposed controls; MyEIRA, Malaysian Epidemiological Investigation of Rheumatoid Arthritis; OR (95% CI), odds ratio and 95% confidence interval, adjusted for ethnicity and formal education by using conditional logistic regression; RA, rheumatoid arthritis. The "any SE alleles group" was defined by the presence of either one or two HLA-DRB1*01:01, *01:02, *01:07, *04:01, *04:04, *04:05, *04:08, *04:10, *10:01, and/or *10:03. The "HLA-DRB1*04:05 group" was defined by the presence of either one or two HLA-DRB1*04:05 allele.

Too et al. Arthritis Research & Therapy 2012 14:R89   doi:10.1186/ar3813